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Of course it can’t buy you love, and it 
may be the root of all evil, but on this we can 
agree: Money can get things done. 
It might, in fact, spur a solution to pet 
overpopulation and unnecessary euthanasia. 
That’s the hope of the Found Animals 
Foundation, a Los Angeles-based nonprofit 
founded by Gary Michelson, a billionaire spi-
nal surgeon who made his fortune patenting 
medical devices. Incorporated in 2005 after 
Michelson saw the animal issues caused by 
Hurricane Katrina and was moved to help, 
Found Animals offers a variety of programs, 
from adoption to pet identification, aimed at 
minimizing or ending shelter euthanasia. (The 
“found” in the organization’s name, says 
executive director Aimee Gilbreath, reflects 
both the promise of its microchip program 
and Michelson’s affection 
for the song “Amazing 
Grace,” which includes the 
line, “I once was lost, but 
now am found.”) 
In late 2008, the foun-
dation announced an eye-
popping brass r ing: the 
Michelson Prize and Grants 
in Reproductive Biology. The 
prize promised $25 million 
to the first entity to develop 
a low-cost, single-dose, nonsurgical method of 
permanently sterilizing cats and dogs. The proj-
ect made another $50 million available in grants 
for related research. “The prize is out there to 
motivate people to go after the Holy Grail, and 
the grant program is there to make sure they 
have the resources to pursue 
that lofty goal,” Gilbreath 
says. She’s confident the 
prize will be awarded within 
five years, but notes it will 
take at least another two 
years beyond that to get a 
product on the market. 
In the edited interview 
that follows, Gilbreath, a 
former biotechnology re-
searcher and business con-
sultant who became the foundation’s first 
employee, and Shirley Johnston, an expert on 
animal reproduction who oversees the prize 
and grants program, discuss the project’s 
progress with Animal Sheltering associate 
editor James Hettinger. 
Million-Dollar Ideas
Michelson Prize and Grants program spurs research into nonsurgical spay/neuter
The tools of the spay/neuter trade might be changing. The Michelson Prize and Grants program is putting up millions of dollars to inspire 
researchers to devise a nonsurgical alternative to conventional surgery.


































































Animal Sheltering: Give us a thumbnail 
description of the Michelson Prize and 
Grants program. 
Aimee Gilbreath: When [Gary Michelson] 
got interested in how to keep so many pets 
from being euthanized in shelters, he started 
looking at weak points in the system, and 
realized that affordability and accessibility 
of spay and neuter was an issue. He started 
thinking that technology has got to have a 
solution to this that is nonsurgical, afford-
able, and easy to deploy in a field setting. 
That was the genesis of the Michelson Prize 
and Grants program. 
Shirley Johnston: In the history of the world, 
there has never been such [an] amount of 
money available to study dog and cat repro-
duction. Our program is trying to get the word 
out to not only scientists who have worked 
in the field of dog and cat reproduction in 
the past, but also people that work on basic 
cellular mechanisms, people that work in 
human reproduction, to try and find innova-
tive ways that we can discover a single-dose, 
nonsurgical sterilant. To date we’ve approved 
about 15 proposals. And we’ve got funding 
in place around the United States, and also in 
Argentina and Australia—researchers there 
that have successfully applied for our grants.
What form are you envisioning?  
Would this be a shot? A pill? 
Gilbreath: We actually try really hard to be 
agnostic about what approach might ulti-
mately carry the day. We are open to any 
nonsurgical method, whether that would be 
an injectable, a pill, some sort of medical de-
vice, some sort of very small implant. We re-
ally don’t have a preconceived notion of how 
this problem gets solved. 
Do you think this will ultimately be 
cheaper than conventional surgery?
Gilbreath: That is our hope, and one of the 
requirements for winning the prize is that it 
has a reasonable manufacturing cost. 
How affordable do you think this  
would be? 
Johnston: We hope that it will be in the 
neighborhood of $5 to $10 [per dose] when 
Executive director Aimee Gilbreath says the 
Found Animals Foundation—reflecting the 
wishes of its founder, Gary Michelson—
seeks innovative solutions to the problem of 
shelter euthanasia. 
Tracking the Immune System
Michael Munks didn’t hear about 
the Michelson Prize and Grants
through a science journal or a grants 
website. He got the word from a 
decidedly less academic source.
“Crazily enough, I first heard
about this when I was watching 
Saturday Night Live.” On a “Weekend
Update” segment in October 2008, 
“they were mentioning that Gary
Michelson was offering this $75 mil-
lion prize and grants for nonsurgical 
sterilization of cats and dogs,” he 
recalls. “So then they were making a 
joke about how the cats and dogs had 
put together $100 million to hire a hit
man to take out Gary Michelson.”
But for Munks, an immunolo-
gist and research fellow who studies
viruses and the immune system’s
response to them at National Jewish 
Health in Denver, the thought of ap-
plying the concept of immunocontra-
ception to cats and dogs was no joke. 
He put together a proposal and in late
2009 got a four-year Michelson grant 
for more than $700,000.
The idea of immunocontraception,
Munks explains, is to trick the immune 
system into deactivating part of the 
reproductive system. If you can create 
an immune response that inactivates
the eggs or the hormones that regu-
late reproduction, you can essentially
“use the animal’s immune system to 
sterilize itself,” he says.
Munks is proposing a herpesvirus 
to create a nonsurgical sterilant for cats 
and dogs—an approach he says other 
researchers found effective in mice. 
Michael Munks
Shirley Johnston acknowledges that developing 
a nonsurgical way to permanently disable 
the reproductive systems of cats and dogs 
is a difficult task, but she’s impressed with 
the quality of the proposals received by the 
Michelson Prize and Grants program. 
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manufactured on a large scale. We are pre-
pared to award the prize for something up to 
about $30. 
Are you picturing a day when this non-
surgical method would actually replace 
conventional surgeries? 
Gilbreath: It’s not necessarily our intention to 
replace surgical spay/neuter. It’s our intention 
to extend the reach to places and to people 
where surgical techniques don’t work well 
now. You could envision a product coming 
out of this—just for example—that was great 
for feral cats, but maybe not great for owned 
cats. It could be that owned cats will continue 
to get surgical spay and neuter, but there’ll be 
a great option for feral cat caretakers. 
 
What do you see as the obstacles to this 
nonsurgical solution? Is it a scientific 
problem, or a matter of the funding not 
being there to do the research? 
Seeking a ‘Magic Bullet’
His lab might focus on tiny fruit flies, but 
William Ja is thinking big.
Normally, he uses fruit flies to study
human aging, nutrition, and disease.
And now Ja has diversified to join the
researchers seeking a nonsurgical sterilant
for dogs and cats through the Michelson 
project, which awarded him a two-year
grant of more than $200,000.
Ja, an assistant professor at Scripps
Research Institute in Jupiter, Fla., recalls
thinking the prize money was “amazing”
when he spotted a Michelson program ad
in a scientific journal in late 2008. He and
some colleagues jokingly kicked around
some ideas over dinner. It was the kind of
talk that often ends at the table, but Ja
decided to investigate further.
Borrowing from cancer research, he
eventually pitched the Michelson funders 
the idea of developing a “magic bullet”
(technically a toxin-ligand conjugate) that
would target crucial reproductive cells 
in the gonads of cats and dogs, causing 
sterilization.
Ja acknowledges that developing a
single drug that permanently takes out 
male and female reproduction in two dif-
ferent species is a daunting task, but he
is confident that someone will devise at 
least a partial solution to the Michelson 
program’s challenge. “I think it should 
be doable, given the examples of sterility 
that occur in nature,” he says. “… And 




















































































































Gilbreath: I think it’s probably a combina-
tion. Nonsurgical products for humans are 
out there, and they’ve been out there for 40 
years. If you can do it for humans, I have no 
doubt that it is technologically possible to do 
it for pets. I have to think that a lot of it has 
been technology, and funding to really moti-
vate people to apply cutting-edge technology 
to that issue. 
Johnston: It’s not easy to completely dis-
able the reproductive systems. In nature, the 
reproductive systems have a lot of ability to 
rebound, for survival of the species. 
Secondly, we have mandated a thor-
oughly high standard in looking at both the 
male and female dog and cat. Dogs and cats 
are real different, and males and females are 
real different, and so to give a single injection 
of something that will safely and permanently 
knock out their [reproductive capability] is re-
ally a big challenge. 
The money is as important, perhaps, 
as the other two. I’ve worked in dog and 
cat reproduction for nearly 40 years now, 
and people have done good research his-
torically, all over the world, in trying to find 
safe contraceptive agents. But in my career 
at universities you would scramble to get 
a $10,000 to $50,000 grant, and now we 
are making available a quarter of a million 
dollars a year for three to four years. We’re 
really getting some traction in that regard; 
we’ve really had some quite brilliant pro-
posals come in that we think may be able 
to solve this challenge.  
What would happen if nobody wins the 
$25 million prize?
Gilbreath: The grant program would con-
tinue, and it could be that we have products 
that come out of grant-funded research that 
do not meet all of the criteria for the prize, 
but that would have an impact on the issue. 
We could very well choose to commercialize 
some products, for example, if [they] only 
worked in cats. That could still be a very 
useful product. 
What’s your impression of how the 
project is going so far? 
Gilbreath: We’re seeing exactly what we had 
hoped for, which is people that were work-
ing on technology that could be relevant, but 
had no idea that this problem existed, actu-
ally having that moment of inspiration, and 
saying, “Oh, this compound that I’m develop-
ing for ovarian cancer treatment kills repro-
ductive cells, so I bet that maybe with some 
tweaks, you could use it to sterilize animals, 
because I know that a side effect [of] ovarian 
cancer treatment is sterility.” 
Are you optimistic that you’re going to 
find what you’re looking for? 
Johnston: I’m really optimistic. I was [ini-
tially] negative about this whole process. I 
turned down a position on the board origi-
nally, because I thought it was like [saying 
to] somebody, “Oh, we’ll give you $25 mil-
lion to turn lead into gold.” But I have since 
come to recognize that in the last 10 to 15 
years, science has advanced on so many 
fronts that now I really do believe we’re 
going to award this prize. AS










At the Found Animals Foundation, 
the Michelson Prize and Grants pro-
gram is seeking a nonsurgical
way to sterilize dogs and cats.
The connection wasn’t immedi-
ately clear.
But the Michelson project “stuck
someplace in the back of my head”
after Struthers heard about it, and
eventually he realized there could be 
a link to his firm’s work. Crinetics, a 
small startup firm founded in 2010 in 
San Diego, was working on an anti-
ovarian cancer drug that might have
a side effect of rendering women 
sterile. While the side effect wasn’t 
an intended component for its human
applications, Struthers, the firm’s
president and chief scientific officer, 
wondered if the drug might cause ste-
rility in dogs and cats. 
The Michelson program awarded 
Crinetics a two-year research grant of
more than $540,000. In a time when 
funding is tight, Struthers credits 
the Found Animals Foundation with
catching the eyes of researchers “who
are normally just thinking about hu-
mans, and making them think about
what they can do for our pets.”
While he’s not on the front lines,
Struthers says he’s learning how im-
portant a nonsurgical sterilant could
be in the battle against pet overpopu-
lation. No matter how efficiently its
practitioners work, spaying and neu-
tering is still a surgical procedure, he
notes. “You can only go so fast.”
“It’s not necessarily our 
intention to replace 
surgical spay/neuter. It’s 
our intention to extend 
the reach to places 
and to people where 
surgical techniques 
don’t work well now.”
— AIMEE GILBREATH
Scott Struthers
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